Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624000812594p
Ethics application status
Not yet submitted
Date submitted
17/06/2024
Date registered
2/07/2024
Date last updated
2/07/2024
Date data sharing statement initially provided
2/07/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
Assessing the effects of a broccoli sprout extract on flow-mediated dilation
Query!
Scientific title
Assessing the effects of a broccoli sprout extract on endothelial function in healthy non-pregnant and pregnant women, and pregnant women with a hypertensive disorder of pregnancy
Query!
Secondary ID [1]
312345
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
hypertension in pregnancy
334115
0
Query!
Condition category
Condition code
Reproductive Health and Childbirth
330789
330789
0
0
Query!
Fetal medicine and complications of pregnancy
Query!
Cardiovascular
330869
330869
0
0
Query!
Hypertension
Query!
Alternative and Complementary Medicine
330870
330870
0
0
Query!
Other alternative and complementary medicine
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Participants will consume a single dose of a commercially available broccoli sprout extract with supervision by research staff. The extract is detailed below:
- 2 capsules of GeneActiv Formulation E by Cell-Logic - 1400mg broccoli sprout supplement total sulforaphane dose 21mg.
Query!
Intervention code [1]
328833
0
Treatment: Other
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
338550
0
Change in endothelial function after a single dose of a broccoli sprout extract in women.
Query!
Assessment method [1]
338550
0
Ultrasound scans of Flow-Mediated Dilation of the brachial artery.
Query!
Timepoint [1]
338550
0
Before (baseline) and 2-3 hours after consumption of the intervention.
Query!
Secondary outcome [1]
436448
0
Concentration of sulforaphane in peripheral maternal blood sample.
Query!
Assessment method [1]
436448
0
Liquid chromatography mass spectrometry.
Query!
Timepoint [1]
436448
0
2-3 hours after consumption of the intervention.
Query!
Secondary outcome [2]
436449
0
Measure any change in blood pressure from baseline after intervention.
Query!
Assessment method [2]
436449
0
Uscome BP+ supra-systolic oscillometric central blood pressure monitoring device
Query!
Timepoint [2]
436449
0
Before (baseline) and 2-3 hours after consumption of the intervention.
Query!
Eligibility
Key inclusion criteria
Group 1: Healthy, non-pregnant women
• Not pregnant.
• Deemed capable of understanding the information provided and able to give written informed consent (with interpreter use as required).
• Body mass index (BMI) between 18 – 35kg/m2.
• 18 years old and over
Group 2: Healthy, pregnant women
• Singleton pregnancy
• Gestation between 28+0 and 36+0 weeks pregnant.
• Normal mid-trimester morphology scan, with no detectable significant anomalies.
• Deemed capable of understanding the information provided and able to give written informed consent (with interpreter use as required).
• Booking body mass index (BMI) between 18 and 35kg/m2.
• 18 years old and over.
Group 3: Pregnant women with a hypertensive disorder of pregnancy
• Singleton pregnancy
• Gestation between 28+0 and 36+6 weeks pregnant.
• Normal mid-trimester morphology scan, with no detectable significant anomalies.
• Deemed capable of understanding the information provided and able to give written informed consent (with interpreter use as required).
• Booking body mass index (BMI) between 18 and 35kg/m2.
• 18 years old and over.
• Diagnosis of preeclampsia or clinical hypertension as defined by the according to the Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) guidelines.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Group 1: Healthy, non-pregnant women
• Younger than 18 years old
• Body mass index (BMI) < 18 or > 35kg/m2.
• Confirmed or suspected pregnancy.
• Current use of broccoli sprout extract supplement.
• Contraindications to use (e.g., intolerance of broccoli).
• Significant uncertainty in ensuring gestational age is within limits.
• Unwillingness or inability to follow the procedures outlined in the PICF.
• Mentally, cognitively or legally incapacitated or ineligible to provide informed consent.
• Co-recruitment/participation in another clinical trial where there is a pharmaceutical or herbal or nutritional intervention (such trial interventions would also include: multi-vitamins, minerals, complementary and alternative medicines).
Group 2: Healthy, pregnant women
• Nil major complications of pregnancy including but not limited to:
o Fetal growth restriction estimated fetal weight <10th centile or AC (abdominal circumference) <5th
o Preeclampsia/HELLP syndrome (haemolysis elevated liver enzymes low platelet syndrome)
o Gestational diabetes on insulin on >20units insulin/day
o PPROM (preterm pre-labour rupture of membranes) within 7 days ago
o Chorioamnionitis
o Stillbirth or intrauterine fetal death
o Suspected or confirmed congenital infection of pregnancy (i.e. CMV, syphilis, rubella)
o Unstable major placenta praevia or vasa praevia
o Hypertensive disorder of pregnancy on >1 regular anti-hypertensive treatment
o Abnormal umbilical artery doppler i.e. elevated umbilical artery doppler pulsatility index (UA PI >95th), absent end-diastolic flow or reversal of end-diastolic flow, or a reduced middle cerebral artery pulsatility index (MCA PI <5th) or abnormal ductus venosus (DV)
• Renal or hepatic dysfunction.
• Current use of broccoli sprout extract supplement.
• Contraindications to use (e.g., intolerance of broccoli).
• Significant uncertainty in ensuring gestational age is within limits.
• Unwillingness or inability to follow the procedures outlined in the PICF.
• Mentally, cognitively or legally incapacitated or ineligible to provide informed consent.
• Co-recruitment/participation in another clinical trial where there is a pharmaceutical or herbal or nutritional intervention (such trial interventions would also include: multi-vitamins, minerals, complementary and alternative medicines).
Group 3: Pregnant women with a hypertensive disorder of pregnancy
• Nil major complications of pregnancy including but not limited to:
o Fetal growth restriction estimated fetal weight <10th centile or AC (abdominal circumference) <5th
o Gestational diabetes on insulin on >20units insulin/day
o PPROM (preterm pre-labour rupture of membranes) within 7 days ago
o Chorioamnionitis
o Stillbirth or intrauterine fetal death
o Suspected or confirmed congenital infection of pregnancy (i.e. CMV, syphilis, rubella)
o Unstable major placenta praevia or vasa praevia
o Abnormal umbilical artery doppler i.e. elevated umbilical artery doppler pulsatility index (UA PI >95th), absent end-diastolic flow or reversal of end-diastolic flow, or a reduced middle cerebral artery pulsatility index (MCA PI <5th) or abnormal ductus venosus (DV)
• Eclampsia
• Current use of broccoli sprout extract supplement.
• Contraindications to use (e.g., intolerance of broccoli).
• Significant uncertainty in ensuring gestational age is within limits.
• Unwillingness or inability to follow the procedures outlined in the PICF.
• Mentally, cognitively or legally incapacitated or ineligible to provide informed consent.
• Co-recruitment/participation in another clinical trial where there is a pharmaceutical or herbal or nutritional intervention (such trial interventions would also include: multi-vitamins, minerals, complementary and alternative medicines).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/11/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
1/11/2026
Query!
Actual
Query!
Date of last data collection
Anticipated
1/11/2026
Query!
Actual
Query!
Sample size
Target
30
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
26692
0
Monash Medical Centre - Clayton campus - Clayton
Query!
Recruitment hospital [2]
26693
0
Jessie McPherson Private Hospital - Clayton
Query!
Recruitment postcode(s) [1]
42733
0
3168 - Clayton
Query!
Funding & Sponsors
Funding source category [1]
316746
0
University
Query!
Name [1]
316746
0
Monash University
Query!
Address [1]
316746
0
Query!
Country [1]
316746
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Monash Health
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
318962
0
None
Query!
Name [1]
318962
0
Query!
Address [1]
318962
0
Query!
Country [1]
318962
0
Query!
Ethics approval
Ethics application status
Not yet submitted
Query!
Ethics committee name [1]
315517
0
Monash Health Human Research Ethics Committee A
Query!
Ethics committee address [1]
315517
0
https://monashhealth.org/research/resources/resource-library/
Query!
Ethics committee country [1]
315517
0
Australia
Query!
Date submitted for ethics approval [1]
315517
0
01/08/2024
Query!
Approval date [1]
315517
0
Query!
Ethics approval number [1]
315517
0
Query!
Summary
Brief summary
Sulforaphane is a naturally occurring compound found in cruciferous vegetables such as broccoli, and has potent anti-inflammatory and antioxidant effects. Sulforaphane is administered in the form of broccoli sprout supplements as they're cheap, room temperature stable and have a proven safety profile in clinical trials outside of pregnancy including cancer and autism spectrum disorder. This trial will use non-invasive clinical methodologies to assess the vasculature in women both before and after a dose of a broccoli sprout extract. We would like to recruit up to 30 women for this trial (non-pregnant, pregnant, pregnant with hypertension) to assess blood pressure, collect one blood sample, and assess flow mediated dilation. This will assess whether a single dose of a broccoli sprout extract has immediate effects on the vasculature. We hypothesise that a single dose of a broccoli sprout extract will not affect blood pressure but will increase flow-mediated dilation in all non-pregnant and pregnant women.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
134950
0
Dr Sarah Marshall
Query!
Address
134950
0
Translational Research Facility, Monash University/Monash Health, 27-31 Wright Street Clayton 3168, Victoria
Query!
Country
134950
0
Australia
Query!
Phone
134950
0
+61 385722792
Query!
Fax
134950
0
Query!
Email
134950
0
[email protected]
Query!
Contact person for public queries
Name
134951
0
Sarah Marshall
Query!
Address
134951
0
Translational Research Facility, Monash University/Monash Health, 27-31 Wright Street Clayton 3168, Victoria
Query!
Country
134951
0
Australia
Query!
Phone
134951
0
+61 385722792
Query!
Fax
134951
0
Query!
Email
134951
0
[email protected]
Query!
Contact person for scientific queries
Name
134952
0
Sarah Marshall
Query!
Address
134952
0
Translational Research Facility, Monash University/Monash Health, 27-31 Wright Street Clayton 3168, Victoria
Query!
Country
134952
0
Australia
Query!
Phone
134952
0
+61 385722792
Query!
Fax
134952
0
Query!
Email
134952
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Data collection from individuals will be combined to have meaningful outcomes. An individuals data will not be made available but results will be published in a non-identifiable manner after completion of the project.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF